152 related articles for article (PubMed ID: 11061890)
1. Use of the complex between prostate specific antigen and alpha 1-protease inhibitor for screening prostate cancer.
Finne P; Zhang WM; Auvinen A; Leinonen J; Määttänen L; Rannikko S; Tammela TL; Stenman UH
J Urol; 2000 Dec; 164(6):1956-60. PubMed ID: 11061890
[TBL] [Abstract][Full Text] [Related]
2. Characterization and determination of the complex between prostate-specific antigen and alpha 1-protease inhibitor in benign and malignant prostatic diseases.
Zhang WM; Finne P; Leinonen J; Stenman UH
Scand J Clin Lab Invest Suppl; 2000; 233():51-8. PubMed ID: 11317942
[TBL] [Abstract][Full Text] [Related]
3. Serum human glandular kallikrein (hK2) and insulin-like growth factor 1 (IGF-1) improve the discrimination between prostate cancer and benign prostatic hyperplasia in combination with total and %free PSA.
Scorilas A; Plebani M; Mazza S; Basso D; Soosaipillai AR; Katsaros N; Pagano F; Diamandis EP
Prostate; 2003 Feb; 54(3):220-9. PubMed ID: 12518327
[TBL] [Abstract][Full Text] [Related]
4. Serum sialic acid and prostate-specific antigen in differential diagnosis of benign prostate hyperplasia and prostate cancer.
Romppanen J; Haapalainen T; Punnonen K; Penttilä I
Anticancer Res; 2002; 22(1A):415-20. PubMed ID: 12017325
[TBL] [Abstract][Full Text] [Related]
5. Serial prostate specific antigen, free-to-total prostate specific antigen ratio and complexed prostate specific antigen for the diagnosis of prostate cancer.
Ellis WJ; Etzioni R; Vessella RL; Hu C; Goodman GE
J Urol; 2001 Jul; 166(1):93-8; discussion 98-9. PubMed ID: 11435831
[TBL] [Abstract][Full Text] [Related]
6. Measurement of insulin-like growth factor axis does not enhance specificity of PSA-based prostate cancer screening.
Oliver SE; Holly J; Peters TJ; Donovan J; Persad R; Gillatt D; Pearce A; Hamdy FC; Neal DE; Gunnell D
Urology; 2004 Aug; 64(2):317-22. PubMed ID: 15302487
[TBL] [Abstract][Full Text] [Related]
7. Percent free prostate-specific antigen (PSA) is an accurate predictor of prostate cancer risk in men with serum PSA 2.5 ng/mL and lower.
Walz J; Haese A; Scattoni V; Steuber T; Chun FK; Briganti A; Montorsi F; Graefen M; Huland H; Karakiewicz PI
Cancer; 2008 Nov; 113(10):2695-703. PubMed ID: 18853417
[TBL] [Abstract][Full Text] [Related]
8. Stability of free and total prostate specific antigen in serum from patients with prostate carcinoma and benign hyperplasia.
Paus E; Nilsson O; Børmer OP; Fosså SD; Otnes B; Skovlund E
J Urol; 1998 May; 159(5):1599-605. PubMed ID: 9554362
[TBL] [Abstract][Full Text] [Related]
9. Complexed prostate specific antigen provides significant enhancement of specificity compared with total prostate specific antigen for detecting prostate cancer.
Brawer MK; Cheli CD; Neaman IE; Goldblatt J; Smith C; Schwartz MK; Bruzek DJ; Morris DL; Sokoll LJ; Chan DW; Yeung KK; Partin AW; Allard WJ
J Urol; 2000 May; 163(5):1476-80. PubMed ID: 10751861
[TBL] [Abstract][Full Text] [Related]
10. Measurement of prostate specific antigen complexed to alpha1-antichymotrypsin to avoid unnecessary biopsy in patients with serum prostate specific antigen levels 4-20 ng/mL.
Nakano Y; Okamura K; Takamura S; Okamoto N; Narishima M; Yoshino Y; Hattori R; Ono Y; Ohshima S; Nagasaka T
Int J Urol; 2005 Aug; 12(8):721-7. PubMed ID: 16174045
[TBL] [Abstract][Full Text] [Related]
11. Serum BPSA outperforms both total PSA and free PSA as a predictor of prostatic enlargement in men without prostate cancer.
Canto EI; Singh H; Shariat SF; Lamb DJ; Mikolajczyk SD; Linton HJ; Rittenhouse HG; Kadmon D; Miles BJ; Slawin KM
Urology; 2004 May; 63(5):905-10; discussion 910-1. PubMed ID: 15134977
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of proprostate specific antigen for early detection of prostate cancer in men with a total prostate specific antigen range of 4.0 to 10.0 ng/ml.
Khan MA; Partin AW; Rittenhouse HG; Mikolajczyk SD; Sokoll LJ; Chan DW; Veltri RW
J Urol; 2003 Sep; 170(3):723-6. PubMed ID: 12913682
[TBL] [Abstract][Full Text] [Related]
13. A multicenter clinical trial on the use of alpha1-antichymotrypsin-prostate-specific antigen in prostate cancer diagnosis.
Lein M; Jung K; Hammerer P; Graefen M; Semjonow A; Stieber P; Ossendorf M; Luboldt HJ; Brux B; Stephan C; Schnorr D; Loening SA
Prostate; 2001 May; 47(2):77-84. PubMed ID: 11340629
[TBL] [Abstract][Full Text] [Related]
14. Specificity of serum prostate-specific antigen determination in the Finnish prostate cancer screening trial.
Määttänen L; Hakama M; Tammela TL; Ruutu M; Ala-Opas M; Juusela H; Martikainen P; Stenman UH; Auvinen A
Br J Cancer; 2007 Jan; 96(1):56-60. PubMed ID: 17213825
[TBL] [Abstract][Full Text] [Related]
15. Prospective evaluation of prostate cancer detection by prostate specific antigen related parameters: comparison in serum and plasma samples.
Egawa S; Suyama K; Matsumoto K; Kuwao S; Baba S
J Urol; 2002 Jan; 167(1):97-102. PubMed ID: 11743284
[TBL] [Abstract][Full Text] [Related]
16. Comparison of several combinations of free, complexed, and total PSA in the diagnosis of prostate cancer in patients with urologic symptoms.
Filella X; Truan D; Alcover J; Quintó L; Molina R; Luque P; Coca F; Ballesta AM
Urology; 2004 Jun; 63(6):1100-3; discussion 1103-4. PubMed ID: 15183958
[TBL] [Abstract][Full Text] [Related]
17. Combining biomarkers to detect disease with application to prostate cancer.
Etzioni R; Kooperberg C; Pepe M; Smith R; Gann PH
Biostatistics; 2003 Oct; 4(4):523-38. PubMed ID: 14557109
[TBL] [Abstract][Full Text] [Related]
18. The significance of prostate-specific antigen alpha-1-antichymotrypsin complex and its indices for the detection of prostate cancer.
Yamanaka K; Yamada Y; Kobayashi Y; Ueno K; Takechi Y; Hasegawa E; Chikahira Y
Hinyokika Kiyo; 2003 Jan; 49(1):5-10. PubMed ID: 12629773
[TBL] [Abstract][Full Text] [Related]
19. Prostate-specific antigen (PSA) complexed to alpha1-antichymotrypsin improves prostate cancer detection using total PSA in Japanese patients with total PSA levels of 2.0-4.0 ng/mL.
Kobayashi T; Kamoto T; Nishizawa K; Mitsumori K; Ogura K; Ide Y
BJU Int; 2005 Apr; 95(6):761-5. PubMed ID: 15794778
[TBL] [Abstract][Full Text] [Related]
20. Strategies combining total and percent free prostate specific antigen for detecting prostate cancer: a prospective evaluation.
Gann PH; Ma J; Catalona WJ; Stampfer MJ
J Urol; 2002 Jun; 167(6):2427-34. PubMed ID: 11992051
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
